Phathom Pharmaceuticals Inc
PHAT8.920USD
+4.229+90.19%
收盘 06/06, 16:00（美东）报价延迟15分钟
621.17M总市值
亏损市盈率 TTM
关于 Phathom Pharmaceuticals Inc 公司
Phathom Pharmaceuticals, Inc. 是一家生物制药公司。该公司专注于开发和商业化新型胃肠道 (GI) 疾病治疗方法。该公司的候选产品包括 VOQUEZNA、VOQUEZNA TRIPLE PAK 和 VOQUEZNA DUAL PAK。其候选产品 VOQUEZNA 含有沃诺拉赞，这是一种口服小分子钾竞争性酸阻滞剂 (PCAB)。PCAB 是一种阻断胃酸分泌的新型药物。沃诺拉赞在治疗糜烂性胃食管反流病 (糜烂性 GERD) 以及与抗生素联合治疗幽门螺杆菌 (H. pylori) 感染方面也表现出临床益处。GERD 和 H. pylori 感染是两种最常见的酸性胃肠道疾病。GERD 是一种因酸性胃内容物反流引起令人困扰的症状和/或并发症而引发的疾病。幽门螺杆菌是一种细菌病原体。
公司简介
公司代码PHAT
公司名称Phathom Pharmaceuticals Inc
上市日期Oct 25, 2019
成立日期2018
CEOMr. Steven Basta
员工数量427
证券类型Ordinary Share
年结日Oct 25
公司地址100 Campus Drive
城市FLORHAM PARK
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编07932
电话18777428466
网址https://www.phathompharma.com/
公司代码PHAT
上市日期Oct 25, 2019
成立日期2018
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Azmi Nabulsi
Dr. Azmi Nabulsi
Co-Founder, Chief Operating Officer
Co-Founder, Chief Operating Officer
929.34K
-2.52%
Dr. Asit Parikh, M.D., Ph.D.
Dr. Asit Parikh, M.D., Ph.D.
Independent Director
Independent Director
113.50K
+10.19%
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Independent Director
Independent Director
67.50K
+18.42%
Ms. Molly Henderson, CPA
Ms. Molly Henderson, CPA
Chief Financial and Business Officer
Chief Financial and Business Officer
62.79K
-43.33%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
46.51K
+29.16%
Mr. Michael F. (Mike) Cola
Mr. Michael F. (Mike) Cola
Independent Chairman of the Board
Independent Chairman of the Board
39.80K
+35.84%
Mr. Mark Stenhouse
Mr. Mark Stenhouse
Independent Director
Independent Director
30.00K
+53.85%
Mr. Theodore R. (Ted) Schroeder
Mr. Theodore R. (Ted) Schroeder
Independent Director
Independent Director
21.00K
--
Ms. Heidi K. Kunz
Ms. Heidi K. Kunz
Independent Director
Independent Director
--
--
Mr. Steven Basta
Mr. Steven Basta
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Azmi Nabulsi
Dr. Azmi Nabulsi
Co-Founder, Chief Operating Officer
Co-Founder, Chief Operating Officer
929.34K
-2.52%
Dr. Asit Parikh, M.D., Ph.D.
Dr. Asit Parikh, M.D., Ph.D.
Independent Director
Independent Director
113.50K
+10.19%
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Independent Director
Independent Director
67.50K
+18.42%
Ms. Molly Henderson, CPA
Ms. Molly Henderson, CPA
Chief Financial and Business Officer
Chief Financial and Business Officer
62.79K
-43.33%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
46.51K
+29.16%
Mr. Michael F. (Mike) Cola
Mr. Michael F. (Mike) Cola
Independent Chairman of the Board
Independent Chairman of the Board
39.80K
+35.84%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 6月6日 周五
更新时间: 6月6日 周五
持股股东
股东类型
持股股东
股东统计
占比
Frazier Life Sciences Management, L.P.
17.15%
Medicxi Ventures (UK) LLP
10.69%
Abingworth Management Limited
5.01%
Invesco Advisers, Inc.
4.80%
BlackRock Institutional Trust Company, N.A.
4.17%
Other
58.18%
持股股东
股东统计
占比
Frazier Life Sciences Management, L.P.
17.15%
Medicxi Ventures (UK) LLP
10.69%
Abingworth Management Limited
5.01%
Invesco Advisers, Inc.
4.80%
BlackRock Institutional Trust Company, N.A.
4.17%
Other
58.18%
股东类型
股东统计
占比
Venture Capital
20.26%
Investment Advisor
18.82%
Private Equity
17.76%
Investment Advisor/Hedge Fund
17.55%
Hedge Fund
8.13%
Individual Investor
4.28%
Research Firm
2.58%
Bank and Trust
0.39%
Pension Fund
0.27%
Other
9.96%
机构持股
更新时间: 3月4日 周二
更新时间: 3月4日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q1
309
70.28M
101.09%
-12.22M
2024Q4
311
70.95M
103.79%
-11.79M
2024Q3
293
76.11M
113.29%
+9.50M
2024Q2
284
61.82M
105.14%
-1.53M
2024Q1
280
58.85M
100.56%
-3.74M
2023Q4
274
57.52M
100.58%
-4.32M
2023Q3
267
60.33M
119.18%
-6.87M
2023Q2
263
58.95M
120.15%
+1.98M
2023Q1
253
46.63M
112.72%
-8.47M
2022Q4
251
44.09M
112.53%
-3.76M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Frazier Life Sciences Management, L.P.
10.11M
14.52%
--
--
Dec 31, 2024
Medicxi Ventures (UK) LLP
7.46M
10.72%
--
--
Dec 31, 2024
Abingworth Management Limited
3.50M
5.02%
--
--
Dec 31, 2024
Invesco Advisers, Inc.
3.37M
4.84%
-146.50K
-4.17%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.08M
4.42%
+355.55K
+13.06%
Dec 31, 2024
The Vanguard Group, Inc.
2.77M
3.98%
+83.24K
+3.10%
Dec 31, 2024
Ensign Peak Advisors, Inc.
2.53M
3.63%
-54.33K
-2.10%
Dec 31, 2024
New Enterprise Associates (NEA)
1.96M
2.81%
--
--
Dec 31, 2024
Wasatch Global Investors Inc
1.56M
2.24%
+1.31M
+531.29%
Dec 31, 2024
683 Capital Management LLC
1.02M
1.47%
+15.00K
+1.49%
Dec 31, 2024
查看更多
持股ETF
更新时间: 6月6日 周五
更新时间: 6月6日 周五
机构名称
占比
Simplify Propel Opportunities ETF
4.82%
Virtus LifeSci Biotech Products ETF
0.93%
iShares Micro-Cap ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
查看更多
Simplify Propel Opportunities ETF
占比4.82%
Virtus LifeSci Biotech Products ETF
占比0.93%
iShares Micro-Cap ETF
占比0.04%
Invesco Nasdaq Biotechnology ETF
占比0.03%
ProShares Ultra Nasdaq Biotechnology
占比0.03%
iShares Biotechnology ETF
占比0.02%
ProShares UltraPro Russell2000
占比0.01%
iShares Russell 2000 ETF
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
Schwab U.S. Small-Cap ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
